Radequinil
Alternative Names: AC-3933; AVE 3933; Resequinil; SX 3933Latest Information Update: 20 Apr 2009
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Dainippon Sumitomo Pharma; sanofi-aventis
- Class Antidementias; Naphthyridines; Neuroprotectants; Nootropics; Oxadiazoles; Small molecules
- Mechanism of Action GABA A receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dementia
Most Recent Events
- 17 Apr 2009 Discontinued - Phase-II for Dementia in Europe (PO)
- 17 Apr 2009 Discontinued - Phase-II for Dementia in Japan (PO)
- 17 Apr 2009 Discontinued - Phase-II for Dementia in USA (PO)